Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate - pivotal Phase 3 contra ...
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive ReS ...
Initiation of Phase 1b Study of GT-02287 in Parkinson’s patients expected by end of 2024BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage ...
Net loss from continuing operations was $ (20.5) million and $ (38.9) million for the three and nine months ended September 30, 2024, respectively, compared to $ (8.2) million and $ (45.3) million for ...